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Abstract.Duchenne muscular dystrophy is an X-linked, recessive muscular dystrophy in which the absence of the dystrophin
protein leads to fibrosis, inflammation and oxidative stress, resulting in loss of muscle tissue. Drug repurposing, i.e. using
drugs already approved for other disorders, is attractive as it decreases development time. Recent studies suggested that
simvastatin, a cholesterol lowering drug used for cardiovascular diseases, has beneficial effects on several parameters in mdx
mice. To validate properly the effectiveness of simvastatin, two independent labs tested the effects of 12-week simvastatin
treatment in either young (starting at 4 weeks of age) or adult (starting at 12 weeks of age) mdx mice. In neither study
were benefits of simvastatin treatment observed on muscle function, histology or expression of genes involved in fibrosis,
regeneration, oxidative stress and autophagy. Unexpectedly, although the treatment protocol was similar, simvastatin plasma
levels were found to be much lower than observed in a previous study. In conclusion, in two laboratories, simvastatin did not
ameliorate disease pathology in mdx mice, which could either be due to the ineffectiveness of simvastatin itself or due to the
low simvastatin plasma levels following oral administration via the food.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is a pro-
gressive muscle wasting disorder affecting around 1
in 5000 new-born boys [1, 2]. Patients are usually
diagnosed around 3–4 years of age, lose ambula-
tion around 10 years of age and die before 30 years
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of age due to respiratory and/or cardiac failure [3].
Out-of-frame mutations or premature stop codons
in the DMD gene cause the absence of a functional
dystrophin protein, which is crucial for muscle fibre
stability [4, 5]. The absence of dystrophin triggers
pathological pathways leading to fibrosis and chronic
inflammation, which in turn results in reduced regen-
eration and disrupted calcium homeostasis [6].
Although corticosteroids have increased the life
expectancy of Duchenne boys, no effective treatment
is currently available [7, 8]. Only four medicines aim-
ing to correct the absence of the dystrophin protein
have been authorised by regulatory authorities, but
these are only applicable to a subset of patients and
have moderate effects [9, 10]. This underlines the
medical need for Duchenne patients.
In the absence of primary therapies aiming at re-
storing the missing protein, therapies addressing
other parts of the disease pathology are of interest.
These compounds could be beneficial on their own or,
in the future, support dystrophin-restoring therapies.
Repurposing of drugs authorised for other disorders
is especially attractive, since these drugs can be devel-
oped quicker, as there is already knowledge on their
safety and pharmacokinetics [11]. However, proper
investigation of these drugs in non-clinical studies is
essential before moving into clinical trials [12].
Statins are 3-hydroxy-3-methylglutaryl (HMG)-
CoA reductase inhibitors which have the ability to
lower LDL cholesterol synthesis. They are therefore
used for the treatment of cardiovascular disorders,
also in children [13]. They also have been reported
to have inhibitory effects on inflammation, oxidative
stress and fibrosis and to enhance autophagy [14–16],
making them a potential repurposing compound for
the treatment of DMD.
Previous studies by Whitehead et al. have shown
that simvastatin treatment results in improved mus-
cle function and decreased muscle damage in the
mdx mouse model [17] and acts on several parts of
the disease pathology, i.e. fibrosis, inflammation and
oxidative stress [18]. However, it is good practise to
validate promising findings in independent laborato-
ries [19–21]. This manuscript describes the findings
of two studies (conducted in two independent labora-
tories) to evaluate the potential effect of simvastatin in
mdx mice, using a set of complementary experiments.
Surprisingly, despite using similar dosing and admin-
istration routes to those used in the previous studies,
we were unable to replicate the previous findings.
In addition, the serum levels of simvastatin found in
our experiments were very low compared to those
reported by Whitehead et al., which may contribute
to the lack of reproducibility.
MATERIALS AND METHODS
Animals and simvastatin treatment
Experiments performed in the Wells laboratory
were approved by the Royal Veterinary College
Animal Welfare and Ethical Review Body and
by the UK Home Office (PPL 70/7777). Experi-
ments in the Aartsma-Rus laboratory were approved
by the Animal Experiment Committee (Dierexperi-
mentencommissie) of the Leiden University Medical
Center (permit #13211) and executed following EU-
guidelines. The Wells laboratory used mdx male mice
(C57Bl/10ScSn background) from a long-standing
internal colony and C57Bl/10ScSn male wild type
controls from Envigo. Mice were held in a minimum
disease unit in open-top cages with environmental
enrichment, at 20.5◦C with 12-hour dark-light cycles.
Water was provided ad libitum. A power calculation
based on previously observed variation determined a
sample size of a minimum of 10 mice per group for
a 20% effect size, allowing for a 20% loss of some
samples due to unexpected problems (e.g. incomplete
muscle physiology recordings, sample losses or any
animal deaths). Personnel performing any of the tests
listed below were blinded to group identity and any
decisions to remove abnormal data were made prior
to unblinding. There were no deaths during dosing
and no sample losses. However, one recording for
the TA physiology in the mdx control group was lost
due to the mouse dying during anaesthesia and one
set of recordings of TA physiology in the mdx con-
trol group was removed as grossly abnormal (a loss
of force at the higher frequencies). A failure of the
force transducer for the in vitro system led to incor-
rect recordings for two mice each in the simvastatin
and control mdx groups and these data were removed.
In the Aartsma-Rus laboratory, C57Bl/10ScSn-
DMDmdx /J (mdx) and C57Bl/10ScSn-DMD/J (wild
type) males were used for all experiments. Mice were
bred by the animal facility of the Leiden University
Medical Center and were housed in individually ven-
tilated cages at 20.5◦C with 12-hour dark-light cycles.
Water was provided ad libitum. All efforts were made
to minimize suffering. Group sizes were based on
previously observed variation in fibrosis levels in the
diaphragm of mdx mice. To demonstrate a 20% effect
size, a group size of 6 mice was required. Where
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During the experiment one mouse in the simvastatin-
treated group and one wild type died, due to problems
unrelated to treatment. All other animals are included
in the analyses.
The simvastatin used at the Royal Veterinary Col-
lege was purchased from Sigma-Aldrich, Switzerland
(#PHR1438), and was mixed with breeding rodent
diet containing 5.5 kcal% fat (#3336, Provimi Kliba
SA, Switzerland) at a concentration of 80 mg/kg. At
LUMC simvastatin powder (#S0509, TCI America,
United States) was mixed with standard rodent diet
containing 10 kcal% fat (Research Diets, Inc, United
States) at a concentration of 80 mg/kg.
For the oral gavage experiment mice were treated
with 8 mg/kg simvastatin activated by hydrolysis of
the lactone group as previously described [17].
Study design
A schematic overview of the study design at the
RVC and LUMC respectively, is shown in Fig. S1.
Male mdx mice were randomly divided into 2
groups at the age of 12 weeks (RVC) or 4 weeks
(LUMC), whereby mice of the same litter were
assigned to different treatment groups. One group
was fed the diet containing 80 mg/kg simvastatin
and the other group control diet (identical but with-
out simvastatin). A wild type control group fed with
control diet was taken along as a reference group.
After 12 weeks of treatment (age 24 or 16 weeks)
mice were sacrificed and muscles were isolated. For
an overview of the outcome measures determined at
the RVC and LUMC respectively, see Table S1.
For determination of plasma levels separate 14-
week old male mice were gavaged in the afternoon
with 8 mg/kg of simvastatin, activated as previously
described [17], and blood samples were taken 30, 60
and 135 min later by cardiac puncture under very
deep isoflurane anaesthesia. Blood was placed imme-
diately in Lithium Heparin BD Microtainer Tubes,
inverted several times and placed on ice. Mice were
killed by cervical dislocation. Bloods were spun for 5
min at 2000g before plasma was removed and stored
at –80◦C before being sent to Keystone Bioanalytical,
Inc. (North Wales, PA 19454, USA).
Functional tests
At the RVC, at 4 and 8 weeks of treatment mice
were subjected in the morning to a four paw hang
test as described previously [22] and TREAT-NMD
standard operating procedure DMD M.2.1.005 [23].
The mouse was placed on a grid, which was then
turned upside down above a cage filled with bedding.
The test ended when a hanging time of 600 s was
achieved or, upon earlier fall, after three sessions.
The holding impulse associated with the hang test
equals the hang time multiplied by the body weight
(given as Newtons sec; conversion factor –9.806 x
10-3 Newtons/gm).
Respiratory function analysis
At the LUMC, after 3, 6, 9 and 12 weeks of
treatment respiratory rate and tidal amplitude were
assessed with non-invasive whole-body plethysmog-
raphy in unrestrained animals (RM-80; Columbus
Instruments, OH, USA). After 30 s acclimatiza-
tion, the respiration signal was recorded for 120 s.
The signal was digitized using a Minidigi digitizer
and AXOSCOPE 10 software (Axon Instruments/
Molecular Devices, CA, USA) and analysed with the
event detection feature of the Clampfit 10 program
(Axon Instruments/Molecular Devices).
Muscle physiology
At the RVC, treated mdx mice, control mdx mice
and control wild type mice were tested at 24
weeks old with the analysis of tibialis anterior (TA)
and diaphragm physiology performed as previously
described [24–26]. Briefly, in mice anaesthetised
with a mixture of fentanyl/fluanisone (Hypnorm,
Vetapharma, Leeds, UK) and midazolam (Hyp-
novel, Roche, Welwyn Garden City, UK) delivered
intraperitoneally, the distal tendon of the TA was
released and tied to a 4.0 braided surgical silk loop.
The sciatic nerve was exposed and the connection to
the spinal cord was cut as well as all the branches
except for the common peroneal nerve. The anaes-
thetised mouse was placed on a thermopad (Harvard
Apparatus, Edenbridge, UK) to maintain body tem-
perature at 37◦C. The foot was secured to a platform
and the knee immobilized using a large sewing needle
underneath the patella tendon. Bipolar platinum elec-
trodes were placed on the sciatic nerve to stimulate
the muscle.
Once surgically prepared, the loop on the TA
tendon was attached to a 305B dual-mode servomo-
tor transducer (Aurora Scientific, Aurora, Ontario,
Canada) via a custom-made steel s-hook. Optimal
muscle length (Lo) was determined by increasing
muscle length and stimulation voltage until the max-
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force–frequency relationship, TA muscles were stim-
ulated at different frequencies, delivered 1 min apart
(1, 10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz)
using a 701C stimulator (Aurora, Scientific). Max-
imal isometric force (Po) was determined from the
plateau of the force–frequency curve. Muscle fibre
cross-sectional area (CSA in cm2) was determined by
using the following formula: muscle weight (g)/[dia
fibre length (Lf; cm) x 0.6 x 1.06 (g/cm3)]. The 0.6 is
the correction for the pennation angle [27]. Specific
isometric force (N/cm2) was calculated by dividing
the absolute force (N) at each stimulation frequency
by TA muscle cross-sectional area. Once Po had been
obtained, the muscle was subject to eccentric (length-
ening) contractions. The TA muscle was stimulated
at 120 Hz for 500 ms before lengthening the muscle
by 10% of the Lo at a velocity of 0.5 Lo s–1 for a
further 200 ms, once the stimulation had ended the
Lo returned at a rate of –0.5 Lo s–1. Between each
contraction a 2 min rest period was permitted to avoid
muscle fatigue. A total of 10 eccentric contractions
were performed on each mouse. After each eccen-
tric contraction, the maximum isometric force was
measured and expressed as a percentage of the initial
maximum isometric force achieved at the start of the
protocol, prior to the first eccentric contraction.
After completing the TA muscle physiology, the
mouse was killed by cervical dislocation. TA mus-
cles were removed and immediately weighed prior
to snap-freezing in isopentane pre-chilled in liq-
uid nitrogen. The whole diaphragm including the
attached ribs was removed and placed in a wax based
dissection dish containing cold Ringer’s buffer. The
diaphragm was pinned, and a 3–4 mm strip was cut
from the central tendon to the ribs along the orienta-
tion of the muscle fibres. A custom made 4 mm wide
stainless steel wire coat hanger was tied to the ribs
using 4-0 surgical braided silk thread and a custom
made elongated steel s-hook ( 4 cm) was attached
to the central tendon. The muscle was suspended
between two platinum electrodes in a water jack-
eted organ bath containing Ringer’s solution, which
was continuously perfused with 95%O2/5%CO2 and
maintained at 28◦C. The central tendon was anchored
to the platform base (via the elongated S-hook),
whilst the costal margin was attached to the lever arm
of a 300C dual-mode servomoter transducer through
the stainless steel coat hanger in the 800A in vitro
muscle apparatus (both Aurora Scientific). Electrical
stimulation was generated through the two plat-
inum electrodes, using square-wave pulses of 0.02
ms. Data acquisition and control of the servomotor
were conducted using a Lab-View-based DMC pro-
gram (Dynamic muscle control and Data Acquisition,
Aurora Scientific).
The diaphragm strip was left to equilibrate for 10
min prior to a warm-up protocol consisting of 3 sub-
maximal contractions at 50 Hz, 500 ms duration, with
each contraction delivered one minute apart. After
defining the optimal voltage (16 V), muscle length
(Lo) was determined by increasing the muscle length
until a maximal twitch force was achieved. The force-
frequency relationship was evaluated by stimulating
the muscle at the same set of frequencies as for the TA.
Maximal isometric force (Po) was determined from
the plateau of the force-frequency curve. Resistance
to eccentric contraction-induced muscle damage was
assessed by stimulating the diaphragm in the same
protocol as the TA but at 100 Hz.
Diaphragm strips were removed from the water
bath and the muscle carefully dissected away from
the rib and central tendon. The muscle was blotted to
remove excess liquid and immediately weighed prior
to snap-freezing in isopentane pre-chilled in liquid
nitrogen.
Muscle fibre cross-sectional area (CSA in cm2)
was determined as for the TA but without a cor-
rection for pennation angle as the diaphragm is not
a pennate muscle. Specific isometric force (N/cm2)
was calculated by dividing the absolute force (N)
at each stimulation frequency by diaphragm muscle
fibre cross-sectional area.
At the LUMC, directly after killing the mice
using CO2 asphyxiation, the contraction force of left
phrenic nerve–hemidiaphragms with a strip of tho-
rax left attached was recorded in Ringer’s medium
at room temperature (20–22◦C), continuously bub-
bled with 95% O2 and 5% CO2. The muscles were
pinned down with multiple small pins through the
thorax strip into the silicone rubber-lined bottom of
a 10 mL Ringer’s medium containing Petri dish.
The central tendon was attached via a hook and
thread to a force transducer (type K30, Harvard
Apparatus–Hugo Sachs Elektronik, Germany). The
signal was amplified by a TAM-A bridge amplifier
(Harvard Apparatus) and digitized by a Digi-
data 1440 digitizer (Axon Instruments/Molecular
Devices) connected to a personal computer run-
ning Axoscope 10 data-acquisition software (Axon
Instruments/Molecular Devices). The phrenic nerve
was stimulated via a bipolar electrode with rect-
angular voltage pulse of 100 s duration from a
computer-controlled programmable stimulator via an
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the minimal stimulus voltage amplitude at which
the preparation started to contract, using 1 s/40
Hz tetanic stimulations, was determined. This was
mostly around 0.5–1 V. The stimulus amplitude was
then increased in small voltage steps to determine the
amplitude at which the tetanic contraction no longer
increased (typically 2 V). The voltage was then set
to 10 V to assure supramaximal stimulation of all
axons in the nerve during the entire experiment. To
determine the optimal length of the muscle for pro-
ducing maximal tetanic contraction, the muscle was
stretched in small increments, using a Vernier control,
each time followed by a 1 s/40 Hz tetanic stimu-
lation. When the tetanic force no longer increased
upon a length increment, no further lengthening was
performed, and this optimal length was kept dur-
ing the following experiment. Subsequently, every
5 min a 40 Hz nerve stimulus train of 7 s dura-
tion was applied and the tetanic contraction was
recorded when it remained stable for at least 15 min.
Thereafter, a stimulus protocol was applied of 7 s
stimulations at 1, 2, 5, 10, 20, 40, 60, 80 and 100 Hz,
with a 30 s pause between each stimulation. Peak val-
ues and area-under-the-curves of the responses were
determined using Clampfit 10 software (Axon Instru-
ments/Molecular Devices).
Simvastatin measurement in plasma
For the RVC, simvastatin and simvastatin acid
levels were measured in mouse lithium heparin
plasma using electrospray ionisation mass liquid
chromatography with tandem mass spectrometry
(ESI LC-MS/MS). LC-MS/MS for the RVC sam-
ples was performed by Keystone Bioanalytical, Inc.
(North Wales, Pennsylvania, USA) and analysed by
Solid Biosciences Inc. (Cambridge, Massachusetts,
USA).
At LUMC, blood was taken via the vena cava
directly after sacrifice and collected in K2EDTA BD
Microtainer™ tubes (Thermo Fisher Scientific Inc.,
the Netherlands), and centrifuged at 13000 rpm for 5
min at 4◦C to generate plasma. Citric acid (Citric acid
ACS reagent, Sigma Aldrich, the Netherlands) was
added at a concentration of 10 mg/mL and stored at
–80◦C until further processing. Simvastatin and inter-
nal standards were isolated by liquid-liquid extraction
using methyl t-butyl ether as a solvent and dried
supernatant was reconstituted in MeOH/water/acetic
acid. An autosampler (SIL-30AC, Shimadzu, Japan),
ZORBAX StableBond Phenyl columns (Agilent)
HPLC pump (LC-20AD, Shimadzu) and tandem MS
(API 5500 QTRAP, AB Sciex LLC) were used for
mass spectrometry analysis.
Hydroxyproline assay
Hydroxyproline content was assayed essentially as
described by Reddy and Enwemeka [28]. Diaphragm
muscles (from treated and untreated mdx mice, and
wild type controls) were pulverised under liquid
nitrogen. Frozen tissue powders (10–20 mg) were
mixed with 20 volumes (v/w) of distilled water and
a 5 L aliquot was collected for protein assay (DC,
BioRad). Remaining tissue suspension was mixed
with an equal volume of 10 N HCl and transferred
to gas-tight glass vials, then heated to 130◦C for
at least 3 hours to allow complete acid hydrolysis.
50 L aliquots of hydrolysed solution were trans-
ferred (in duplicate) to clear, flat-bottomed 96-well
plates (Corning) and placed in a well-ventilated
60◦C oven to dry (30–40 min). A standard dilution
series of pure hydroxyproline (dissolved in distilled
water) was included on every plate. Hydroxyproline
was oxidised by addition of 100 L chloramine-T
buffer (prepared as described below) followed by
incubation at room temperature for 20 min with gen-
tle shaking. Colour was developed by addition of
100 L of p-dimethylaminobenzaldehyde (DMAB,
Ehrlich’s reagent, see below) and incubation at 60◦C
for 20 min. Absorbance was read at 550 nm using a
plate reader (Tecan). Chloramine-T buffer (prepared
fresh): 1.27 g chloramine-T dissolved in 20 mL of
50% n-propanol, then added to 80 mL of acetate-
citrate buffer (120 g sodium acetate trihydrate, 12
mL acetic acid, 34 g sodium hydroxide, 46 g citric
acid, 1 L final volume, pH 6.5).
Ehrlich’s reagent (prepared fresh): 15 g DMAB in
100 mL of 2 : 1 (v/v) n-propanol:perchloric acid. All
reagent volumes can be adjusted accordingly depend-
ing on number of plates to be assayed.
RNA isolation and quantitative PCR
At RVC, RNA was isolated from frozen mus-
cle powders (as prepared for hydroxyproline assay,
above) using TRIzol reagent (Thermofisher) accord-
ing to manufacturer’s instructions, with inclusion of
an additional chloroform extraction (1 : 1) follow-
ing phase separation. RNA yield and purity were
confirmed by nanodrop (ND1000). cDNA was syn-
thesised from 800 ng RNA using the Nanoscript2
RT kit (Primerdesign, United Kingdom). SYBR
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mastermix (Primerdesign, United Kingdom) in a
LightCycler CFX384 (BioRad, United Kingdom),
using 8 ng cDNA per well (assuming 1 : 1 conver-
sion). Following 3 min hot-start, PCR used 40 cycles
of 95◦C (15 s), 60◦C (20 s) and 72◦C (20 s). All
qPCR runs included a melt curve following the final
cycle. Cq values were determined via regression and
normalized to the geometric mean of CDC40 and
Fbxo38 (taken from the geNormPLUS set, Primerde-
sign, United Kingdom).
At LUMC, muscle sections were collected in 1.4
mm Zirconium Beads prefilled tubes (OPS Diag-
nostics, Lebanon, USA) and disrupted in TRIsure
isolation reagent (GCBioetech, the Netherlands)
using a MagNA Lyser (Roche Diagnostics, the
Netherlands). Total RNA was isolated and cleaned
up by applying a NucleoSpin RNA II kit (Macherey-
Nagel, Germany) according to the manufacturer’s
instruction. cDNA was synthesised from 0.5 g of
total RNA using random N6 primers (Thermo fisher
scientific) and Bioscript enzyme (GCBiotech, the
Netherlands) according to the manufacturer’s instruc-
tions. qPCR was performed using SensiMix reagents
(GCBiotech) and the LightCycler 480 (Roche), using
a program consisting of 45 cycles of 95◦C (10 s),
58◦C (30 s) and 72◦C (20 s). The LinReg qPCR
method was used to analyse gene expression levels
and values were normalized utilizing the housekeep-
ing gene Hmbs after confirming equal expression
between samples from wild type and mdx, and
simvastatin-treated and untreated mdx mice.
Gene expression levels were determined for Fbxo
32 (Atrogin-1), Cd68, Col1a1, Col3a1, Lgals3, Map1
lc3b, Myh1, Myh2, Myh3, Myh4, Myh7, Myh8, Nox2,
Nox4. Primer sequences are provided in Table S2.
Sirius Red staining
At LUMC, directly after sacrifice diaphragm
muscles were, embedded in Optimal Cutting Temper-
ature (OCT) compound (TissueTek; Sakura Finetek,
CA,USA), snap frozen in liquid nitrogen cooled
isopentane. Sections (8 m thickness) were cut using
with a cryostat (Leica CM3050 S Research Cryo-
stat; the Netherlands). Interleaving sections were
collected for RNA and protein analysis. Levels of col-
lagen were quantified by Sirius Red staining. Sections
were fixed in 4% paraformaldehyde for 10 min, fixed
in 100% ethanol for 5 min and air dried for 30 min.
Sections were washed in deionised water and stained
for 45 min using Sirius Red solution (Direct Red 80;
Sigma-Aldrich). Thereafter, they were washed with
0.5% acetic acid water for 5 min and rinsed in deion-
ized water. Sections underwent dehydration steps
using ethanol (80%–90%–100%) and after incuba-
tion in xylene for two times 5 min, were mounted in
Pertex mounting medium (VWR International B.V).
The stained muscle sections were imaged using a
BZ-X700 fluorescent microscope (Keyence) at ten
times magnification and processed and stitched using
BZ-X Analyzer (Keyence). Adobe Photoshop CC
2018 (Adobe Systems Corporation, San Jose, CA,
United States) was used for background correction
and ImageJ software (NIH) for analysis. Sirius Red
positive areas were normalised to the total area. Two
examiners independently assessed the images and the
average of their results was used for analysis.
Protein analysis
At LUMC, TA muscles were homogenised in
buffer containing 100 mM Tris-HCl (pH 6.8)- 20%
(w/v) sodium dodecyl sulfate (SDS) in 1.4 mm Zirco-
nium Beads prefilled Tubes (OPS Diagnostics LLC,
NJ, United States), using a MagNaLyzer (Roche).
Protein concentrations were determined using a
Pierce bicinchoninic acid protein assay kit (Thermo
Fisher Scientific, MA, United States) according to
manufacturer’s instructions. Samples containing
30 g of total protein were prepared in buffer con-
taining 75 mM Tris-HCl (pH 6.8), 15% (w/v) SDS,
20% (v/v) glycerol, 5% (v/v) -Mercaptoethanol,
and 0.001% (w/v) Bromophenol blue and heated
for 5 min at 95◦C. A wild type control containing
5–50% of protein was included. Samples were
loaded on 1.0 mm thick Criterion XT Tris acetate
(poly-acrylamide) gels with a linear resolving gel
gradient of 3–8% (the Netherlands). Gels were run at
75 V ( 0.07 A) for 1 hour and at 150 V ( 0.12 A) for 2
hours on ice. Proteins were blotted onto ready-to-use
Trans-Blot Turbo transfer pack using the Trans-Blot
Turbo system (BioRad) at 2.5 A ( 25 V) for 10
min. Membranes were blocked for 1 hour in buffer
containing 5% Non-fat dried milk powder (Elk;
Campina, the Netherlands). Membranes were washed
once in TBST buffer containing 10 mM Tris-HCl (pH
8.0), 0.15 M NaCl and 0.005% (v/v) Tween20, incu-
bated overnight at 4◦C in primary antibody, washed
3 times in TBST buffer, incubated for 1 hour at 4◦C
in secondary antibody, and washed twice in TBST
and once in TBS. As primary antibodies mouse anti-
gp91[phox] (1 : 4000; #611415, BD Biosciences,
the Netherlands) and rabbit anti-Gapdh [EPR6256]
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and as secondary antibodies IRDye 800CW goat-
anti-mouse IgG (1 : 5000; #P/N 926-32210; LI-COR
Biotechnology, Germany) and IRDye 680TL
goat-anti-rabbit IgG (1 : 10 000; #P/N 926-68021,
LI-COR) were used. Proteins were visualized using
the Odyssey system and software (LI-COR).
Statistical analysis
For statistical analysis RStudio [29] and Prism
7 (GraphPad Software Inc., CA, USA) were used.
Values are presented as means ± standard deviation
(SD). Statistical significance was set at p < 0.05.
Holding impulse, endpoint bodyweight and gene
expression were analysed using a nonparametric
Kruskal-Wallis test and Dunn’s post-hoc correction
for multiple comparison. Protein expression was
compared with an unpaired, two-tailed t-test with
Welch’s correction. In order to model the data most
accurately for bodyweight, eccentric contraction and
tetanic contraction force a log-transformed mixed-
effects model analysis, using the lme4 package
[30] was performed using fixed effects for treat-
ment and fixed and quadratic effects for contraction
number, stimulation frequency or weight (includ-
ing their interactions). Since eccentric contraction
curves showed variability in curvature between mice,
a random intercept and a random contraction number-
effect per mouse was included. Treatments were
compared with an ANOVA test using a likelihood
ratio test. The baseline and maximum force of the
diaphragm and TA were compared using a one-way
ANOVA between treatments groups with Tukey’s
multiple comparison test to correct for multiple
testing.
RESULTS
The dose and route of administration chosen for
these studies (food containing 80 mg/kg simvastatin)
were similar to the previously published study [17].
This led to an intake of 7–10 mg/kg/day, whereby
no differences in total food intake were seen between
the different groups. A daily dose of around 10 mg/kg
would correspond to a dose of 1.2 mg/kg in children
[31] and is thereby within the dose recommended for
the treatment of conditions for which simvastatin has
been approved [13, 32].
Since the diaphragm is the most severely affected
muscle in mdx mice, these were used for most anal-
yses [33].
Fig. 1. Four limb hanging test after 4 and 8 weeks of treatment for
mice started simvastatin treatment at 12 weeks of age (n = 10–11).
No significant differences were seen between the mdx controls and
simvastatin treated mdx mice at either time.
The effect of simvastatin after onset of muscle
damage
First the effect of simvastatin after the onset of
muscle damage was investigated by starting simvas-
tatin treatment at 12 weeks of age (RVC). Mdx mice
were heavier than wild type, but no effect of 12 weeks
of simvastatin treatment was seen on bodyweight
(data not shown).
Functional performance
After 4 and 8 weeks of treatment (16 and 20
weeks of age respectively) the endurance of the mice
was tested using a four limb hanging test. Although
holding impulses were shorter in mdx mice com-
pared to their wild type counterpart, as has been
seen in previous studies [22, 34], no differences
in holding impulse were seen between the control
and simvastatin-treated mdx mice, and there was no
change over time within the groups (Fig. 1).
Muscle physiology
At the endpoint, force frequency relationship (a
measure of muscle strength), and response to eccen-
tric contractions (a measure of membrane integrity),
were determined in the TA by stimulation of the
sciatic nerve in situ in anaesthetised mice, and in
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Fig. 2. Muscle strength and membrane integrity after direct muscle stimulation. Force frequency and response to eccentric contractions
in 24–week old mice after 12 weeks of simvastatin treatment. (A–B) Tibialis anterior (in situ). (C–D) Diaphragm, (in vitro) (n = 8–12).
∗∗p < 0.01, ∗∗∗∗p < 0.0001 compared to wild type mice.
Mdx TA muscles produced significantly less force
and exhibited the expected significant drop in tetanic
strength following eccentric contraction. The force
deficit and sensitivity to eccentric damage was not
prevented by simvastatin treatment (Fig. 2A–B).
In the diaphragm, muscle function was similarly
impaired in mdx mice and again no amelioration was
observed after simvastatin treatment (Fig. 2C–D).
Fibrosis
Fibrosis is a hallmark of DMD, and diaphragms
of mdx mice typically show severe fibrotic accumu-
lation. We measured fibrosis in the diaphragm by
determining the collagen content using a hydroxypro-
line assay, and by expression of collagen type I and III
using qPCR (Fig. 3). As expected, extensive fibrosis
is present in mdx mouse diaphragm, which show an
increased collagen content (Fig. 3A) and expression
of fibrotic markers when compared with wild type
diaphragms (Fig. 3B–C). Simvastatin treatment did
not affect the level of fibrosis.
Inflammation
Inflammation in the muscles is often seen in DMD.
Again a large increase in the expression of the inflam-
matory markers lectin, galactoside binding soluble 3
(Lgals3) and cluster of differentiation 68 (Cd68) was
seen in the diaphragm of the mdx mice. This was not
prevented by simvastatin treatment (Fig. 4).
Degeneration and regeneration
Muscle fibre degeneration and regeneration was
assessed using myosin heavy chain (MHC) expres-
sion. Levels of several different isoforms were
measured in the diaphragm [35, 36]. The expres-
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Fig. 3. Fibrosis. Diaphragm of 24–week old mice after 12 weeks of simvastatin treatment. (A) hydroxyproline content. (B–C) expression of
collagen type I (B) and III (C) (n = 10–12). ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 compared to wild type mice.
Fig. 4. Inflammation. Expression of (A) Lgals3 and (B) CD68 in the diaphragm of 24-week old mice after 12 weeks of simvastatin treatment
(n = 10–12). ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 compared to wild type mice.
MHC was very low in wild type mice, indicat-
ing negligible levels of regeneration are present. In
mdx mice continuous cycles of degeneration and
regeneration are ongoing, leading to high levels of
both forms of MHC (Fig. 5A–B). In adult muscle,
different isoforms are expressed depending on the
type of muscle. Type I (Myh7) is present in slow-
twitch fibres and type IIx (Myh1), IIa (Myh2) and
IIb (Myh4) in fast-twitch fibres. Both the slow-twitch
MHCIβ and fast-twitch MHCIIx were decreased in
mdx diaphragms relative to wild type (Fig. 5C–D),
while no differences were seen in MHCIIa and
MHCIIb (Fig. 5E–F). Simvastatin-treated diaphragms
were essentially indistinguishable from untreated
mdx.
Autophagy and oxidative stress
Autophagy plays a role in the DMD pathology.
Autophagy is impaired in mdx muscles, lead-
ing to muscle atrophy [37]. Induction of atrogin–1
(FBXO32) expression is one of the pathways via
which statins may induce muscle atrophy [38]. In
the quadriceps of mdx mice, however, such an effect
has not been seen [17]. Indeed, atrogin–1 levels in
diaphragm were shown to be lower in mdx mice com-
pared to wild type mice and were not influenced by
simvastatin treatment (Fig. 6A).
Increases in autophagy have been shown to be
associated with induction of microtubule-associated
protein 1 light chain 3 (LC3B) [16, 39]. Indeed,
Whitehead et al. reported an increase in LC3B pro-
tein levels after simvastatin treatment of mdx mice
(though the authors did not examine healthy controls)
[17]. In the present study, no differences in LC3B
gene expression were seen both between mdx and
wild type mice and between simvastatin-treated and
non-treated mdx mice (Fig. 6B).
Another mechanism leading to impaired auto-
phagy is oxidative stress [40, 41]. NADPH oxidases
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Fig. 5. De- and regeneration. Expression of different isoforms of myosin heavy chain in the diaphragm of 24–week old mice after 12 weeks
of simvastatin treatment. (A) embryonic (Myh3). (B) neonatal (Myh8). (C) adult slow-twitch type I (Myh7). (D–F) adult fast-twitch type
IIx (Myh1) (D), IIa (Myh2) (E) and IIb (Myh4) (F) (n = 10–12). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 compared to wild type
mice.
Fig. 6. Autophagy. Expression of (A) atrogin–1 and (B) LC3B in the diaphragm of 24–week old mice after 12 weeks of simvastatin treatment
(n = 10–12). ∗∗p < 0.01 compared to wild type mice.
oxygen species (ROS). Nox2 and Nox4 are two
homologs found in skeletal muscle [42]. Statins
are reported to decrease Nox2 and Nox4, thereby
decreasing ROS and rescuing autophagy [43–45].
Both Nox2 and Nox4 expression were increased in
diaphragms of mdx mice, but these increases were
unaffected by simvastatin treatment (Fig. 7).
The effect of simvastatin during development of
muscle damage
In mdx mice the first signs of muscle dam-
age (necrosis, apoptosis and inflammation) are seen
around three weeks of age. Thereafter, cycles of
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Fig. 7. Oxidative stress. Expression of (A) Nox2 and (B) Nox4 in the diaphragm of 24–week old mice after 12 weeks of simvastatin treatment
(n = 10–12). ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 compared to wild type mice.
around 12 weeks of age, after which the cycling rate
falls. In contrast to DMD patients, mdx muscle recov-
ers relatively well [46]. To investigate the effect of
simvastatin treatment starting at the onset of mus-
cle damage, four-week old mdx mice were treated
with simvastatin for 12 weeks (LUMC). Although
mdx mice gained more weight than wild type mice,
simvastatin treatment did not affect weight gain (data
not shown).
Respiratory function and muscle physiology
During treatment, the respiratory function (rate
and amplitude) of the mice was followed. This
was not affected by simvastatin treatment (data not
shown).
After 12 weeks of treatment starting at four weeks
of age, nerve-stimulated contraction force of the
diaphragm was measured ex vivo. No clear benefits
of simvastatin were observed; however, no reduction
in peak twitch contraction force nor in peak tetanic
contraction force during 7 s at 40 Hz was seen in
mdx muscles (simvastatin-treated and untreated) as
compared to wild type (Fig. 8A–B), even after nor-
malisation for bodyweight (Fig. 8C–D). Similarly, no
clear differences were observed in area-under-the-
curve analysis of the repetitive twitch contractions
or tetanic contractions evoked by multiple frequen-
cies of repetitive nerve stimulation (Fig. 8E). No
differences between the groups were seen in peak
force during tetanic contractions at 40, 60, 80 and
100 Hz nerve stimulation (Fig. 8F). However, a ten-
dency towards a more pronounced muscle fatigue in
the mdx (simvastatin-treated as well as untreated)
muscles, as compared to wild type, was observed
at the higher frequencies (60, 80 and 100 Hz)
(Fig. 8G).
Muscle histology
Fibrosis in 16-week old mice was examined by Sir-
ius Red staining of sections of the diaphragm muscle.
As with 24-week old mice (described above), fibrotic
content is increased in mdx mice compared to wild
type mice. Similarly, simvastatin treatment did not
prevent the development of fibrosis. Similar levels of
fibrosis were detected in both treated and untreated
mdx mice (Fig. 9A–B).
Pathological pathway analysis
In agreement with the changes seen in 24-week old
mice, there was clear deregulation of genes related
to the disease pathology when comparing mdx and
wild type mice. Increased expression of the fibrotic
markers collagen type I and III was seen in mdx
mice (Fig. 9C-D), as were markers of inflammation
(Fig. 10) and MHC-related markers of de- and regen-
eration (Fig. 11). None of these markers were affected
by simvastatin treatment.
In 24–week old mice a downregulation of
atrogin–1 compared to age-matched wild type mice
(indicating impaired autophagy) was seen. In younger
mice a similar trend towards decreased expression
in mdx samples was observed (though this did not
achieve statistical significance), and simvastatin
treatment was comparable with untreated mdx mice
(Fig. 12A). As with 24-week old mice, LC3B expres-
sion was comparable between all groups (Fig. 12B).
As with older mice (Fig. 7), expression of Nox2 and
Nox4 was markedly elevated in mdx diaphragms
when compared with wild type (Fig. 13A–B), and
western blotting for Nox2 showed this increase was
also reflected at the protein level (Fig. 13C–D).
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Fig. 8. Nerve-stimulated muscle strength. Diaphragm of 16–week old mice after 12 weeks of simvastatin treatment. (A) Twitch contraction
force. (B) Peak of the tetanic contraction force evoked by 7 s stimulation at 40 Hz. (C–D) Twitch (C) and tetanic (D) contraction force
normalised to bodyweight. (E) Stimulation frequency-contraction relationship. Area-under-the-curve of 7 s stimulation at the indicated
frequency (F) Peak tetanic contraction force during 7s of 40, 60, 80 and 100 Hz nerve stimulation. (G) Fatigue after 7 s of tetanic contraction
at 40, 60, 80 and 100 Hz nerve stimulation, expressed as percentage of the peak force (n = 5–6). There are no significant differences between







I.E.C. Verhaart et al. / Simvastatin Treatment of mdx Mice 13
Fig. 9. Fibrosis. Diaphragm of 16–week old mice after 12 weeks of simvastatin treatment. (A) Representative images of Sirius Red stained
diaphragms (10x magnification) (B) quantification of collagen content by Sirius Red staining. (C–D) expression of (C) collagen I and (D)
collagen III (n = 5–6). ∗p < 0.05, ∗∗p < 0.01 compared to wild type mice.
Fig. 10. Inflammation. Expression of (A) Lgals3 and (B) CD68 in the diaphragm of 16-week old mice after 12 weeks of simvastatin treatment
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Fig. 11. De- and regeneration. Expression of different isoforms of myosin heavy chain in the diaphragm of 16-week old mice after 12 weeks
of simvastatin treatment. (A) embryonic (Myh3). (B) neonatal (Myh8). (C) adult slow-twitch type I (Myh7). (D–F) adult fast-twitch type
IIx (Myh1) (D), IIa (Myh2) (E) and IIb (Myh4) (F) (n = 5–6). ∗p < 0.05, ∗∗p < 0.01 compared to wild type mice.
Simvastatin plasma levels
Since, in contrast to previously reported results
[17], no effects of simvastatin treatment were ob-
served, it was decided to investigate simvastatin
plasma levels to determine the effectiveness of sim-
vastatin administration routes.
Administration via oral gavage led to high plasma
levels directly after administration, but these declined
rapidly. Two hours and 15 min after oral gav-
age only 12.6% of levels measured after 30 min
remained (Fig. 14A). No later time points were
included.
When simvastatin was administered via the food,
only low levels of simvastatin were observed
(Fig. 14B). In the first part of the experiment plasma
levels were measured two weeks after initiation of
the experiment at two different times points of the
day. Levels were somewhat higher in blood collected
in the morning during the last part of the dark phase
than in the afternoon during the last part of the light
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Fig. 12. Autophagy. Expression of (A) atrogin–1 and (B) LC3B in the diaphragm of 16–week old mice after 12 weeks of simvastatin
treatment (n = 5–6). There are no significant differences between any of the groups.
nocturnal animals and mostly feed during the dark
phase. Levels did not accumulate during treatment.
After 12 weeks of treatment (in the second part of the
experiment) plasma levels were still around 1 ng/mL
(plasma collected during the day) (Fig. 14B).
DISCUSSION
Since promising results were seen with simvas-
tatin treatment in the mdx mouse model at different
stages of the muscle pathology [17], our study tested
simvastatin treatment in mdx mice at different ages
and thereby pathological stages. Clear signs of mus-
cle damage were observed in mdx mice compared
to wild type mice, but in both studies, starting during
and after the onset of muscle damage, no preservation
of muscle function or amelioration of pathology was
seen due to simvastatin treatment. It is known that up
to 30% of humans taking simvastatin experience side
effects in skeletal muscle [47]. In our study in mice no
obvious deleterious effects on muscle were seen, but
given these are dystrophic animals, mild effects may
be masked by more profound disease-related muscle
pathology.
Although previous studies showed a modestly
decreased peak contraction force of mdx diaphragms
during nerve stimulation [48], no clear differences
in comparison to wild type mice could be detected
in the LUMC study. Variation between individual
mice within the groups was substantial, precluding
detection of minor changes (making it difficult to
judge any possible effect of simvastatin). In contrast,
using direct muscle stimulation of muscle strips a
large decrease in contraction force and resistance was
observed in mdx diaphragm when compared to their
wild type counterpart in the RVC study. Similarly,
nerve stimulation showed a large decrease in mdx TA
contraction force and resistance (vs wild type mice).
This is in line with previous results [24, 25, 49]. How-
ever, even with this more sensitive method, no effect
of simvastatin treatment was observed.
Marked alterations in expression of genes involved
in fibrosis, regeneration, autophagy and oxidative
stress were seen in both 12- and 24-week old
mdx mice, relative to age-matched wild type mice.
Although these changes were largely consistent
between both studies, they were more statistically
robust at 24 weeks. This could both be due to the
age of the mice and to the larger group size allowing
detection of smaller differences. One of the proposed
mechanisms by which simvastatin could act on DMD
pathology is counteracting the impaired autophagy
caused by increased oxidative stress [50]. Markers
for autophagy and oxidative stress were, however,
not altered by simvastatin treatment. In addition, no
amelioration of muscle pathology was observed his-
tologically.
Recently a new study, using the same treatment
protocol as the original study [17], showed a pos-
itive effects of simvastatin on cardiomyopathy [51].
However, signs of cardiomyopathy only become clear
in ten-month-old mdx mice and therefore we were
unable to study these aspects here [52].
The lack of simvastatin efficacy revealed by our
studies could be explained by low plasma levels of
drug. Therefore, we investigated the pharmacokinet-
ics of simvastatin. Simvastatin is known to have a
short in vivo half-life [53]. Indeed, in our hands, after
a single dose given via oral gavage plasma levels
dropped rapidly (from 40 ng/mL after 30 min to 5
ng/mL after 2.25 hours). Administration via the food
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Fig. 13. Oxidative stress. 16–week old mice after 12 weeks of simvastatin treatment. (A–B) Gene expression of Nox2 (A) and Nox4 (B)
in the diaphragm. (C–D) Expression of Nox2 protein in the tibialis anterior. Each lane represents an individual mouse (n = 5–6). ∗p < 0.05,
∗∗p < 0.01 compared to wild type mice.
much lower than levels observed in the study reported
by Whitehead and colleagues, where administration
at the same dose in the food resulted in plasma levels
of 400 nM (170 ng/mL), despite total food intake of
the mice being comparable between the studies [17].
It is possible that such high plasma levels are neces-
sary for the beneficial effects reported, but these levels
(obtained after administration via the food) seem sur-
prisingly high, given we and others were unable to
reach such levels even with oral gavage. Other studies
have reported a considerable range of plasma levels
following oral gavage. Panajatovic and colleagues
used this approach to dose three strains of mice with 5
mg/kg daily and found plasma samples collected one
hour after treatment were between 7.05 and 14.7 nM,
equivalent to 3 to 6.25 ng/mL [54]. In contrast, Famey
reported plasma levels of 54.7 ng/mL (equivalent to
129 nM) in mice treated 1 hour earlier by oral gavage
with 2 mg/kg simvastatin [55]. While these values are
closer to those reported by Whitehead et al., our data
suggests it is very unlikely that similar plasma levels
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Fig. 14. Simvastatin plasma levels. (A) At 30 min, 1 hour and 2.25 hour after single oral gavage (8 mg/kg) (n = 3–4). (B) After 2 week
(AM/PM plasma collection) and 12 week treatment with 80 mg/kg simvastatin in the diet. (n = 5–8). ∗p < 0.05
intake of 8–10 mg/kg. Other routes of administration
might lead to higher plasma levels (and could thereby
potentially ameliorate muscle pathology and func-
tion). Oral administration is, however, most relevant
from a clinical perspective [13].
In conclusion, our results show that, in contrast
to previous studies, no beneficial effects of simvas-
tatin treatment were seen in either young or adult mdx
mice.
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